Table 22: Impact of eTools on Other Tests Conducted for Kidney Management.
| Author, Year | Study Design | Length of Follow-up | Sample Size, n (Intervention/Control) | Results (Intervention/Control) | Effect Estimate (95% CI) |
|---|---|---|---|---|---|
| Branger et al, 1999 (32) | Observational | 1 year | 215/60 |
Creatinine levels 106 (0.5)/21 (0.4)measures (per patient) |
Mean difference 0.10 (−0.04 to 0.24) |
| Cebul et al, 2011 (38) | Observational | 1 year | 24,547/2,660 |
Kidney management(microalbumin or ACE inhibitor or ARB) 93.4%/78.2% of patients |
aDiffa 13.3 (8.4–18.3) |
| Herrin et al, 2012 (40) | Observational | 5 years | 10,017/35,033 patient years |
Urinalysis 47.6%/50.6% of patients |
aORb 0.8 (0.7−0.8) |
Abbreviations: ACE, angiotensin-converting enzyme; aDiff, adjusted risk difference; aOR, adjusted odds ratio; ARB, angiotensin receptor blocker; CI, confidence interval; eTool, electronic tool.
a
Adjusted for insurance type, age, sex, race/ethnic group, language preference, estimated household income, and education level.
b
Adjusted for age, sex, insulin usage, and year of study.